stability of ghk cu peptide in solution at room temperature GHK-CU The first order degradation profiles

GHK-Cu dosage spans two distinct administration routes in the research literature injectable systemic protocols and topical application protocols each with its own dosing conventions, concentration ranges, and timing considerations

This method allows for deeper penetration and increased bioavailability compared to topical creams and serums

Anti-Aggression and Anti-Anxiety Effects: Research in animal models indicates potential for modulating behavior

Pealsman A, Hoyo-Vadillo C, Seredenin SB, Gudasheva TA, Ostrovskaya RU, Busciglio J: GVS-111 prevents oxidative damage and apoptosis in normal and Downs syndrome human cortical neurons

Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono

2, 31-60 degrees